Biotech News
Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~ ~ Record Number of Patients and
